Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: Focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 10, 2011, Pages 658-665

  Bai, Yushan ^a   M , M ,qier ^a   Murakami, Hiroya ^b   Iwasa, Masamitsu ^a   Sumi, Shohei ^a   Yamada, Yoshihisa ^a   Ushikoshi, Hiroaki ^a   Aoyama, Takuma ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Uno, Bunji ^b   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adenosine; Cilostazol; Mitochondrial ATP sensitive potassium channels; Myocardial infarct size; Nitric oxide

Indexed keywords

5 HYDROXYDECANOIC ACID; 5 HYDROXYDECANOIC ACID SODIUM SALT; 8 P SULFOPHENYL THEOPHYLLINE; ADENOSINE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CILOSTAZOL; HYDROETHIDINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RABBIT;

ADENOSINE; ANIMALS; CARDIOTONIC AGENTS; DECANOIC ACIDS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; HYDROXY ACIDS; MYOCARDIAL INFARCTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNEL BLOCKERS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RABBITS; REPERFUSION INJURY; SUPEROXIDES; TETRAZOLES; THEOPHYLLINE;

EID: 80053149901     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05550.x     Document Type: Article

References (33)

1. Kimura Y, Tani T, Kanabe T, Watanabe K. Effects of cilostazol on platelet aggregation and experimental thrombosis. Arzneim-Forsch. 1985; 35: 1144-9.
2. Tanaka K, Gotoh F, Fukuuchi Y et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989; 20: 668-763.
3. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwice F. Cilostazol as a unique antithrombotic agent. Curr. Pharm. Des. 2003; 9: 2289-302.
4. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J. Vasc. Surg. 2002; 36: 1283-91.
5. Uchiyama S, Demaerschalk BM, Goto S et al. Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials. J. Stroke. Cerebrovasc. Dis. 2009; 18: 482-90.
6. Shinohara Y, Katayama Y, Uchiyama S et al. CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS2): An aspirin-controlled, double-blind, randomized non-inferiority trial. Lancet. Neurol. 2010; 9: 959-68.
7. Lassila R, Lepantalo M, Lindfors O. Peripheral arterial disease-natural outcome. Acta. Med. Scand. 1986; 220: 295-301.
8. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10years in patients with peripheral arterial disease. N. Engl. J. Med. 1992; 326: 381-6.
9. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84: 350-6.
10. Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, Vanden Hoek TL. ROS and NO trigger early preconditioning: Relationship to mitochondrial KATP channel. Am J. Physiol. Heart. Circ. Physiol. 2003; 284: H299-308.
11. Wang Y, Hirai K, Ashraf M. Activation of mitochondrial ATP-sensitive K(+) channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ. Res. 1999; 85: 731-41.
12. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). J. Am. Coll. Cardiol. 1988; 12: 239-49.
13. Manickavasagam S, Ye Y, Lin Y et al. The Cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc. Drugs Ther. 2007; 21: 321-30.
14. Kariya T, Minatoguchi S, Ohno T et al. Infarct size-reducing effect of ischemic preconditioning is related to alpha1b-adrenoceptors but not to alpha1α-adrenoceptors in rabbits. J. Cardiovasc. Pharmacol. 1997; 30: 437-45.
15. Minatoguchi S, Arai M, Uno Y et al. A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits. Br. J. Pharmacol. 1999; 128: 1667-72.
16. Chen X, Minatoguchi S, Wang N et al. Quinaprilt reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits. J. Cardiovasc. Pharmacol. 2003; 41: 938-45.
17. Wang N, Minatoguchi S, Chen XH et al. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J. Cardiovasc. Pharmacol. 2004; 43: 747-57.
18. Miller FJ Jr, Gutterman DD, Rios C, Heistad DD, Davidson B. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ. Res. 1993; 72: 403-12.
19. Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol. 2000; 36: 351-60.
20. Tsuchida A, Miura T, Miki T, Shimamoto K, Iimura O. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. Cardiovasc. Res. 1992; 26: 456-61.
21. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanism in dogs. J. Am. Coll. Cardiol. 1999; 33: 242-9.
22. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89: 2176-82.
23. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br. J. Pharmacol. 1987; 90: 687-92.
24. Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc. Natl Acad. Sci. USA 1988; 185: 2800-4.
25. Wright CD, Mulsch A, Busse R, Ossswald H. Generation of nitric oxide by human neutrophils. Biochem. Biophys. Res. Commun. 1989; 160: 813-9.
26. Cohen RA, Weisbrod RM. Endothelium inhibits norepinephrine release from adrenergic nerves of rabbit carotid artery. Am. J. Physiol. 1988; 254: H871-8.
27. Takano H, Manchikalapudi S, Tang XL et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 1998; 98: 441-9.
28. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ. Res. 1992; 70: 223-33.
29. Hide EJ, Thiemermann C. Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate. Cardiovasc. Res. 1996; 31: 941-6.
30. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: From adenosine receptor to KATP channel. Annu. Rev. Physiol. 2000; 62: 79-109.
31. Portz SJ, Lesnefsky EJ, VanBenthuysen KM, McMurtry IM, Horowitz LD. Dimethylthiourea, but not dimethylsulfoxide, reduces canine infarct size. Free Radic. Biol. Med. 1989; 7: 53-8.
32. Inoue M, Sato E, Park AM et al. Cross-talk between NO and oxyradicals, a supersystem that regulates energy metabolism and survival of animals. Free Rad. Res. 2000; 33: 757-70.
33. Goto M, Liu Y, Yang Xi-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 1995; 77: 611-21.